The popularity of Sildenafil initially drove a surge for pharma, nevertheless recent developments present a complicated picture for investors. Generic competitors are eating into revenue, and persistent patent https://pennywshk325166.blogunteer.com/39893724/the-blue-pill-and-the-pharmaceutical-industry-a-volatile-play